Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12195057 | 0.88 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12011310 | 0.87 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15247678 | 0.80 | SYK (0.48) | CTSKCTSSREN | |
| SCHEMBL15247712 | 0.80 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12011309 | 0.80 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12194532 | 0.79 | REN (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL464313 | 0.78 | CA1 (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL464207 | 0.77 | CA1 (0.41) | CTSKCTSSCA1CA2CA7 | |
| Benzene SCHEMBL5809252 | 0.75 | CTSK (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL464153 | 0.73 | CTSK (0.54) | CTSKCTSSREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | CTSK 86/4885CTSS 15/4885CA1 3427/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | CTSK 86/4885CTSS 15/4885CA1 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.